Three Years, Seven Acquisitions Later, Cardinal Health Has More Plans In China
This article was originally published in The Pink Sheet Daily
U.S. distributor Cardinal Health goes full speed ahead in China. It has bought local players to tap into the regional market, doubled direct-to-patient pharmacies, and provided pharmacy management services to large hospitals among endeavors in the past three and a half years with more to come.
You may also be interested in...
Major US pharma distributor Cardinal Health is further expanding its regional presence in China, with the country’s rapidly changing operating environment presenting opportunities and challenges.
Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?
SHANGHAI - In what some are calling a transformational event for the China pharma industry, Cardinal Health announced Nov. 29 that it has closed a deal to acquire local private distributor Zuellig Pharma China (Yong Yu in Chinese) for $470 million
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.